InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q1 Results, Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
May 8, 2025
Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for a potential NDA submission under the FDA’s Accelerated Approval pathway for ALS in Q4 2025, supported by survival data and upcoming biomarker analysis. New data also showed CNM-Au8 significantly improved survival in […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in D. Boral Capital Global Conference on May 14
May 7, 2025
Clene (NASDAQ: CLNN) announced it will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. President and CEO Rob Etherington will be available for one-on-one meetings from 9 a.m. to 3 p.m. ET. To view the full press release, visit https://ibn.fm/FK2Q1 About Clene Inc. Clene […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference
April 14, 2025
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases such as ALS and MS, announced that management will deliver a virtual corporate update at the Emerging Growth Conference on April 17, 2025, at 12:00 p.m. EDT. The presentation will include a live Q&A session and will be webcast on Clene’s website and through the […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Evidence of Remyelination, Cognitive and Visual Gains in MS Trial
April 8, 2025
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, announced new evidence of remyelination and neuronal repair in multiple sclerosis (MS) patients treated with CNM-Au8® 30 mg in the long-term extension of the Phase 2 VISIONARY-MS trial. Presented at the AAN 2025 Annual Meeting, the post hoc analyses revealed consistent anatomical and physiological […]
Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference
April 2, 2025
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will participate in the upcoming Jones Las Vegas Technology and Innovation Conference at The Venetian Resort. The […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9
April 1, 2025
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1×1 investor meetings. A webcast of the […]
Clene Inc.’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available for On-Demand Viewing
March 27, 2025
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), announced that its presentation for the Q1 Virtual Investor Summit has been made available for on-demand viewing […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference
March 25, 2025
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data
March 24, 2025
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained limited, but Clene highlighted regulatory progress and survival data supporting CNM-Au8, its gold nanocrystal suspension for ALS. The company expects to meet with the […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval
March 21, 2025
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor […]
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data
March 19, 2025
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has released new data showing that its lead drug candidate, CNM-Au8, significantly extends survival in patients with […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients
March 12, 2025
Clene (NASDAQ: CLNN) Clene Inc. (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significantly extended survival for patients with ALS. The analysis compared patients receiving CNM-Au8 (Regimen C) to a large concurrent control group (Regimen A) and demonstrated a median survival increase of 6.5 […]
Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference
March 12, 2025
Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will attend the 37th Annual Roth Conference, according to a company news release (https://ibn.fm/odbPx). Clene’s management […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Collaborates to Support Potential Accelerated Pathway for ALS Treatment Candidate
March 7, 2025
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data in evaluating its drug candidate, CNM-Au8®, for ALS treatment. Based in Germany, APST operates one of the largest ALS biomarker repositories, which includes data from over 4,300 ALS patients. This collaboration […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference
March 6, 2025
Clene (NASDAQ: CLNN) a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced its participation in the 37th Annual Roth Conference. Management will host a virtual fireside chat on March 18, 2025, at 9:20 a.m. PST and conduct one-on-one investor meetings. Interested parties are encouraged to contact their Roth representative […]
Clene Inc. (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit on March 11
March 5, 2025
Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”), will attend the Q1 Virtual Investor Summit event on March 11 to showcase its latest achievements […]
Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug
February 28, 2025
Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has signed an agreement with APST Research GmbH (“APST”) to support analyses of CNM-Au8’s effects on […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11
February 27, 2025
Clene (NASDAQ: CLNN) announced that CEO Rob Etherington and CFO Morgan Brown will present at the Investor Summit Virtual on March 11, 2025. The event will provide investors with insights into the company’s latest developments and strategic outlook. To view the full press release, visit https://ibn.fm/NzQFl About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Partners with APST Research to Advance ALS Drug Approval Process
February 25, 2025
Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) database in FDA-recommended analyses of CNM-Au8® for treating amyotrophic lateral sclerosis (ALS). APST’s repository includes biomarker data from over 4,300 ALS patients, which will help Clene compare NfL changes in NIH-sponsored Expanded Access Protocol participants […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
January 8, 2025
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)
December 26, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently received additional written guidance and a roadmap from the U.S. Food and Drug Administration’s (“FDA”) Division […]
Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application
December 26, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company has now secured a new $10 million debt facility, enabling the pay-off of another […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility to Advance Neurodegenerative Disease Treatments
December 19, 2024
Clene (NASDAQ: CLNN) has announced a $10 million debt facility with three affiliated entities, set to close by December 20, 2024. The 18-month secured, partially convertible note carries a 12% fixed interest rate, with an interest-only period for the first year. Sixty-five percent of the note is convertible into common stock at $5.67 per share, a […]
Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS
December 13, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), has received additional written guidance and a roadmap from the U.S. Food and Drug Administration’s (“FDA”) Division […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway
December 10, 2024
Clene (NASDAQ: CLNN) received FDA guidance on leveraging data from its ongoing expanded access programs (“EAPs”) to support an accelerated approval application for CNM-Au8, its treatment for ALS. The FDA recommended using neurofilament light chain (“NfL”) biomarker analyses to substantiate the drug’s efficacy. Clene plans to submit additional data in mid-2025, alongside commencing the Phase 3 […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway
November 13, 2024
Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for accelerated approval of CNM-Au8 for ALS, a 1-for-20 reverse stock split to meet Nasdaq requirements, an amended debt facility extending funding into Q2 2025, and a $7.3 […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership
October 24, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced an upcoming meeting with U.S. Food and Drug Administration (“FDA”) leadership. The focus is to […]
Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences
October 18, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) multiple sclerosis (“MS”) and Parkinson’s Disease (“PD”), is participating in two top investor conferences this month to present its latest achievements […]
Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements
October 10, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) multiple sclerosis (“MS”) and Parkinson’s Disease (“PD”), announced the successful closing of a $7.3 million registered direct offering and concurrent private […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
October 9, 2024
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene announced Wednesday morning that it will participate in two investor conferences […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
October 2, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary, Clene Nanomedicine Inc., has closed on a registered direct offering and concurrent private placements. According to the announcement, the transactions consist of common stock and warrants and were with […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
September 30, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused […]
Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
September 24, 2024
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), announced an upcoming meeting with the U.S. Food and Drug Administration (“FDA”) leadership to discuss lead candidate […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
September 16, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, will be meeting in-person with the U.S. Food and Drug Administration (“FDA”) before the end of November 2024. The company announced that the meeting, which will focus on discussions about the development of the […]
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
September 11, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will present at the H.C. Wainwright 26th Annual Global Investment Conference. During the Sept. 9-11 event, Clene management presented the company’s latest achievements and updates, […]
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
September 6, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is making significant strides with its lead candidate, CNM-Au8. This innovative treatment focuses on targeting the nicotinamide adenine dinucleotide (“NAD+”) pathway, which is critical for many mitochondrial functions, including energy production and redox homeostasis. […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company today announced that its management will present at the H.C. […]
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
August 30, 2024
Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial […]
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
August 28, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was recently featured on The BioMedWire Podcast, highlighting the important results of CNM-Au8 trials for both amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), and plans for the future (https://ibn.fm/6OOO1). During the podcast, CEO […]
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
August 22, 2024
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced positive results of two independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, of CNM-Au8 for the treatment of amyotrophic lateral sclerosis (“ALS”) (https://ibn.fm/ktu4u). The new CNM-Au8 biomarker and clinical […]